Browsing Tag
Royalty Pharma
3 posts
Theravance Biopharma cashes out remaining Trelegy royalties in $225m deal with GSK
Theravance Biopharma sells Trelegy royalties to GSK for $225M, unlocking shareholder value and reinforcing its focus on YUPELRI and ampreloxetine.
PTC Therapeutics collaborates with Royalty Pharma in $1.5bn Evrysdi royalty agreement
PTC Therapeutics, Inc. (NASDAQ: PTCT) has forged an agreement with Royalty Pharma plc., monetizing up to a staggering…
Ipsen to acquire American biopharma company Epizyme for $247m
French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration…